Molecular structure of Evogliptin, CAS Number: 1222102-29-5
Evogliptin (CAS 1222102-29-5)
CAS Number:
1222102-29-5
Molecular Weight:
401.42
Molecular Formula:
C19H26F3N3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Evogliptin (CAS 1222102-29-5) References
- Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. | Tan, X. and Hu, J. 2016. Expert Opin Pharmacother. 17: 1285-93. PMID: 27156529
- Modulation of Sirt1/NF-κB interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation. | Nguyen, PA., et al. 2019. Biochem Pharmacol. 168: 452-464. PMID: 31421133
- Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice. | Kim, MJ., et al. 2020. Diabetes Metab J. 44: 186-192. PMID: 31701692
- Altered Structural Expression and Enzymatic Activity Parameters in Quiescent Ulcerative Colitis: Are These Potential Normalization Criteria? | Kjærgaard, S., et al. 2020. Int J Mol Sci. 21: PMID: 32164249
- Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation. | Seo, S., et al. 2020. Exp Mol Med. 52: 1744-1753. PMID: 33051573
- Evogliptin attenuates bleomycin-induced lung fibrosis via inhibiting TGF-β/Smad signaling in fibroblast. | Ba, YD., et al. 2020. Eur Rev Med Pharmacol Sci. 24: 10790-10798. PMID: 33155239
- Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat. | Lee, SJ., et al. 2022. Exp Neurol. 348: 113922. PMID: 34780772
- Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells. | Seo, HY., et al. 2022. Int J Mol Sci. 23: PMID: 36232933
- Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin. | Kim, B., et al. 2023. Diabetes Obes Metab. 25: 1769-1776. PMID: 36852751
- Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice. | Pham, TK., et al. 2023. Exp Mol Med. 55: 767-778. PMID: 37009790
Inhibitor of:
CD26, DPP10, and DPPA4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Evogliptin, 5 mg | sc-507284 | 5 mg | $1060.00 |